Cargando…

Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy

In recent years, continuous glucose monitoring (CGM) has become increasingly available with the introduction of devices that are specifically approved for use during pregnancy. Evidence in the form of randomized-controlled trials and cohort studies continues to build support for the use of CGM durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Jennifer M., Murphy, Helen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957373/
https://www.ncbi.nlm.nih.gov/pubmed/33512267
http://dx.doi.org/10.1089/dia.2020.0667
_version_ 1783664635892727808
author Yamamoto, Jennifer M.
Murphy, Helen R.
author_facet Yamamoto, Jennifer M.
Murphy, Helen R.
author_sort Yamamoto, Jennifer M.
collection PubMed
description In recent years, continuous glucose monitoring (CGM) has become increasingly available with the introduction of devices that are specifically approved for use during pregnancy. Evidence in the form of randomized-controlled trials and cohort studies continues to build support for the use of CGM during pregnancy to improve measures of maternal glycemia as well as obstetric and neonatal outcomes. Based on data from the CGM in pregnant women with type 1 diabetes (CONCEPTT) trial alongside a Swedish cohort study of real-world outcomes of pregnant women with type 1 diabetes, the UK National Institute for Health and Clinical Excellence (NICE) guidelines now recommend that real-time CGM be offered to all pregnant women with type 1 diabetes. Based on these guidelines, all pregnant individuals in the United Kingdom with type 1 diabetes will receive government-funded real-time CGM for a 12-month duration. These guidelines are a game-changer and will continue to facilitate more widespread access to CGM use in the United Kingdom and beyond. This review describes the role of CGM in the management of diabetes in pregnancy, discusses contemporary maternal glucose levels and their relationship with outcomes in diabetes pregnancies, and examines the high-quality, randomized-controlled trial and the real-world clinical data evaluating the impact of CGM use.
format Online
Article
Text
id pubmed-7957373
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-79573732021-03-29 Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy Yamamoto, Jennifer M. Murphy, Helen R. Diabetes Technol Ther Real-World Evidence of Real-Time CGM (rtCGM) Use and Healthcare Cost Implications In recent years, continuous glucose monitoring (CGM) has become increasingly available with the introduction of devices that are specifically approved for use during pregnancy. Evidence in the form of randomized-controlled trials and cohort studies continues to build support for the use of CGM during pregnancy to improve measures of maternal glycemia as well as obstetric and neonatal outcomes. Based on data from the CGM in pregnant women with type 1 diabetes (CONCEPTT) trial alongside a Swedish cohort study of real-world outcomes of pregnant women with type 1 diabetes, the UK National Institute for Health and Clinical Excellence (NICE) guidelines now recommend that real-time CGM be offered to all pregnant women with type 1 diabetes. Based on these guidelines, all pregnant individuals in the United Kingdom with type 1 diabetes will receive government-funded real-time CGM for a 12-month duration. These guidelines are a game-changer and will continue to facilitate more widespread access to CGM use in the United Kingdom and beyond. This review describes the role of CGM in the management of diabetes in pregnancy, discusses contemporary maternal glucose levels and their relationship with outcomes in diabetes pregnancies, and examines the high-quality, randomized-controlled trial and the real-world clinical data evaluating the impact of CGM use. Mary Ann Liebert, Inc., publishers 2021-03-01 2021-03-02 /pmc/articles/PMC7957373/ /pubmed/33512267 http://dx.doi.org/10.1089/dia.2020.0667 Text en © Jennifer M. Yamamoto and Helen R. Murphy, 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Real-World Evidence of Real-Time CGM (rtCGM) Use and Healthcare Cost Implications
Yamamoto, Jennifer M.
Murphy, Helen R.
Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy
title Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy
title_full Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy
title_fullStr Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy
title_full_unstemmed Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy
title_short Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy
title_sort benefits of real-time continuous glucose monitoring in pregnancy
topic Real-World Evidence of Real-Time CGM (rtCGM) Use and Healthcare Cost Implications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957373/
https://www.ncbi.nlm.nih.gov/pubmed/33512267
http://dx.doi.org/10.1089/dia.2020.0667
work_keys_str_mv AT yamamotojenniferm benefitsofrealtimecontinuousglucosemonitoringinpregnancy
AT murphyhelenr benefitsofrealtimecontinuousglucosemonitoringinpregnancy